Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Concert Pharmaceuticals, Inc. (CNCE)

8.37   0 (0%) 03-03 16:00
Open: 8.38 Pre. Close: 8.37
High: 8.55 Low: 8.35
Volume: 0 Market Cap: 402(M)

Technical analysis

as of: 2023-03-31 4:17:40 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 9.87     One year: 9.98
Support: Support1: 8.31    Support2: 6.91
Resistance: Resistance1: 8.45    Resistance2: 8.55
Pivot: 8.37
Moving Average: MA(5): 8.37     MA(20): 8.36
MA(100): 6.35     MA(250): 5.49
MACD: MACD(12,26): 0.1     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 28.4     %D(3): 40.4
RSI: RSI(14): 66.6
52-week: High: 8.55  Low: 2.66
Average Vol(K): 3-Month: 1,999 (K)  10-Days: 1,442 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CNCE ] has closed above bottom band by 48.8%. Bollinger Bands are 94.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.56 - 8.6 8.6 - 8.64
Low: 8.25 - 8.3 8.3 - 8.34
Close: 8.3 - 8.37 8.37 - 8.44

Company Description

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Headline News

Mon, 06 Mar 2023
Sun Pharma completes acquisition of US-based Concert Pharmaceuticals - Business Standard

Thu, 16 Feb 2023
Concert Pharmaceuticals: Negative Spread But Interesting CVR ... - Seeking Alpha

Wed, 15 Feb 2023
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough ... - Business Wire

Mon, 13 Feb 2023
CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the ... - Business Wire

Fri, 20 Jan 2023
Why Concert Pharmaceuticals Stock Rocketed Higher This Week - The Motley Fool

Thu, 19 Jan 2023
Sun Pharma to Acquire Concert Pharmaceuticals (CNCE) for $8 Per ... -

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 48 (M)
Shares Float 44 (M)
% Held by Insiders 3.7 (%)
% Held by Institutions 77 (%)
Shares Short 1,080 (K)
Shares Short P.Month 2,170 (K)

Stock Financials

EPS -3.18
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.77
Profit Margin (%) 0
Operating Margin (%) -288
Return on Assets (ttm) -38.6
Return on Equity (ttm) -108.7
Qtrly Rev. Growth -98.5
Gross Profit (p.s.) -1.15
Sales Per Share 0.66
EBITDA (p.s.) -1.9
Qtrly Earnings Growth 0
Operating Cash Flow -110 (M)
Levered Free Cash Flow -44 (M)

Stock Valuations

PE Ratio -2.65
PEG Ratio 0
Price to Book value 3.01
Price to Sales 12.54
Price to Cash Flow -3.67

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.